News • 23-3-2017

Statin did not convincingly affect verbal or nonverbal memory function

ACC 2017 First study investigating the effects of statins on the CNS using fMRI, showed few differences between atorvastatin 80 mg and placebo in standardised neuropsychological tests. Read more
News • 22-3-2017

New heart failure agent also reduces HbA1c levels

ACC 2017 In addition to its cardiovascular benefits, the ARNI sacubitril/valsartan also reduces HbA1c levels, compared to enalapril. Read more
News • 21-3-2017

No role for aspirin in long-term prevention of recurrent VTE

ACC 2017 In the EINSTEIN CHOICE study, rivaroxaban, at both 20 mg and 10 mg doses, was more effective than aspirin for the prevention of recurrent venous thromboembolism after 6 to 12 months of therapy. Read more

Physical activity and BMI show dose-response association with risk of heart failure

13-3-2017 • Pandey A J Am Coll Cardiol. 2017
In a pooled analysis of individual-level data from 3 prospective studies, a dose–response association between physical activity, BMI, and risk of HF was observed, particularly in HFpEF patients. Read more

Preterm delivery associated to maternal CVD risk

1-3-2017 • Tanz LJ, et al, Circulation, 2017
Preterm delivery is independently predictive of CVD which is only partially explained by postpartum development of traditional CVD risk factors.  Read more

57% decrease in ischaemic stroke incidence by changing risk factors

21-2-2017 • Vangen-Lønne AM, et al, Stroke, 2017
In an analysis from data between 1995 to 2012, changes in risk factors accounted for 57% of the decreased IS incidence and most important contributors were decline in SBP and prevalence of smoking. Read more
News • 22-3-2017

Efficacy of usual care for hypertension enhanced with use of e-counselling tool

ACC 2017 The REACH trial demonstrated that after 12 months of use of an e-counselling programme, hypertensives showed 10 mmHg lower SBP and improvement of other risk factors. Read more
News • 22-3-2017

PCSK9 inhibitor does not affect cognitive functioning in CVD patients, not even at very low LDL-c

ACC 2017 No difference in cognitive function was seen between evolocumab and placebo-treated patients in the EBBINGHAUS trial. No cognitive decline was seen over time in either treatment group. Read more
News • 20-3-2017

CV benefit of consistent LDL-c lowering with PCSK9 antibody in high-risk patients on statins

ACC 2017 The FOURIER trial showed stable LDL-c reduction with evolocumab by about 60% during 3 years in statin-treated CVD patients, and lower CV event rates. event curves continued to diverge over time. Read more

More arterial stiffness in heavy alcohol consumers

2-3-2017 • O’Neill D, et al, JAHA, 2017
Using alcohol consumption data of 25 years, it was found that especially male heavy drinkers have increased arterial stiffness, and over time, pulse wave velocity of non-drinkers increased most.  Read more

E-cigarette use may not be harmless

1-3-2017 • Moheimani RS, et al, JAMA Cardiol, 2017
Habitual e-cigarette use was associated with a shift in cardiac autonomic balance toward sympathetic predominance and increased oxidative stress, both associated with increased CV risk.  Read more

Reduced doses NOAC show similar efficacy and bleeding risk but possibly higher mortality risk

20-2-2017 • Nielsen PB et al., BMJ. 2017
Real-world data show lower dose NOACs associated with similar risk of thromboembolic events and similar or lower rates of bleeding as compared with warfarin in AF, but mortality risk seems higher with NOACs. Read more

Upcoming meetings

Meeting reports & resources

EPCCS 2017 Report of the Cardiovascular Summit held in Dublin, Ireland
EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
All meeting reports...